Seres Therapeutics, Inc.(MCRB)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MCRB Seres Therapeutics, Inc.

未开盘 07-19 16:00:00 EDT

1.23

-0.03

-2.78%

盘后1.23

+0.00+0.41%

19:51 EDT

最高1.29	最低1.15	成交量224.15万
今开1.26	昨收1.26	日振幅11.11%
总市值1.86亿	流通市值1.46亿	总股本1.51亿
成交额272.87万	换手率1.87%	流通股本1.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"MCRB","market":"US","secType":"STK","nameCN":"Seres Therapeutics, Inc.","latestPrice":1.225,"timestamp":1721419200000,"preClose":1.26,"halted":0,"volume":2241518,"hourTrading":{"tag":"盘后","latestPrice":1.23,"preClose":1.225,"latestTime":"19:51 EDT","volume":41076,"amount":51012.3618,"timestamp":1721433104481},"delay":0,"floatShares":119574505,"shares":151447763,"eps":-0.622877,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.035,"latestTime":"07-19 16:00:00 EDT","open":1.26,"high":1.29,"low":1.15,"amount":2728728.9728368,"amplitude":0.111111,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.622877,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721635200000},"adr":0,"listingDate":1435291200000,"adjPreClose":1.26,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":1.25,"preClose":1.26,"latestTime":"09:29 EDT","volume":12259,"amount":15367.790457500001,"timestamp":1721395768425},"postHourTrading":{"tag":"盘后","latestPrice":1.23,"preClose":1.225,"latestTime":"19:51 EDT","volume":41076,"amount":51012.3618,"timestamp":1721433104481},"volumeRatio":0.3106622014890211,"impliedVol":1.7304,"impliedVolPercentile":0.8254},"requestUrl":"/m/hq/s/MCRB","defaultTab":"news","newsList":[{"id":"2441208747","title":"美国研究综述-Ciena, Huntsman, Prog Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2441208747","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441208747?lang=zh_cn&edition=full","pubTime":"2024-06-07 14:54","pubTimestamp":1717743247,"startTime":"0","endTime":"0","summary":"    路透6月7日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Ciena、Huntsman 和 Prog Holdings。要闻             * Capital One Financial Corp   ：BTIG给予该公司中性评级             * Ciena Corp   ：雷蒙德-詹姆斯将其评级从 \"强力买入 \"下调至 \"跑赢大盘\"。* Collegium Pharmaceutical Inc   ：杰富瑞将其评级从 \"持有 \"上调至 \"买入\"。* 亨斯迈公司  ：摩根大通将其评级从减持上调至增持              * Prog Holdings Inc   ：BTIG给予该公司中性评级      以下是路透周五报导的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1914381329.SGD","BK4106","SOFI","CRMT","MCRB","SYF","LU1989764664.SGD","IE00B3S45H60.SGD","IE00BKDWB100.SGD","CIEN","LYFT","BK4104","LU0061474705.USD","MSFT","PRG","AAN","IE00B1BXHZ80.USD","TRGP","HUN","LPRO","RLAY","FTAI","IE00BFSS8Q28.SGD","LU2023250843.SGD","LU0130103400.USD","VSCO","MTN","COF","CPB","MRNA","AFRM","EMR","LZ","UPST","IE0009356076.USD","LRCX","IE0004445239.USD","BRZE","DFS","LU0130102774.USD","PVH","DOCU","ATXI","LU0320765646.SGD","GB00B4LPDJ14.GBP","IE00BJTD4N35.SGD","SJM","COLL","GB00B4QBRK32.GBP","LU0109391861.USD"],"gpt_icon":0},{"id":"2441122337","title":"BUZZ-雀巢健康部门收购粪便移植药片后，Seres 下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2441122337","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441122337?lang=zh_cn&edition=full","pubTime":"2024-06-06 21:27","pubTimestamp":1717680437,"startTime":"0","endTime":"0","summary":"    6月6日 - ** 制药商Seres Therapeutics   股价盘前下跌4.4%至1.1美元 ** 雀巢健康科学公司将购买 MCRB 的 Vowst  的使用权，从而完全有机会使用有史以来第一种替代粪便移植治疗致命细菌感染的药片。** 美国 FDA 去年批准 Vowst 用于预防艰难梭菌感染复发** Seres 于 2021 年与雀巢公司达成一项协议，在美国联合开展药物商业化。** 雀巢公司  将向Seres公司支付一笔未公开的款项，Seres公司还将获得注资。** MCRB公司报告称，该药物在2024年第一季度的净销售额为1010万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCRB","BK4139","BUZZ","03165","NSRGY","BK4212"],"gpt_icon":0},{"id":"2441928637","title":"Seres 将向雀巢健康公司出售细菌感染药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2441928637","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441928637?lang=zh_cn&edition=full","pubTime":"2024-06-06 18:41","pubTimestamp":1717670473,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月6日 - Seres Therapeutics公司  周四表示，该公司已与雀巢健康科学公司就出售细菌感染药物 及相关知识产权达成了不具约束力的谅解备忘录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MCRB","NSRGY","BK4212","03165"],"gpt_icon":0},{"id":"2434404841","title":"奥本海默：维持Seres Therapeutics(MCRB.US)评级，由优于大市调整至优于大市评级, 目标价由5.00美元调整至4.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434404841","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434404841?lang=zh_cn&edition=full","pubTime":"2024-05-10 00:55","pubTimestamp":1715273705,"startTime":"0","endTime":"0","summary":"奥本海默：维持Seres Therapeutics(MCRB.US)评级，由优于大市调整至优于大市评级, 目标价由5.00美元调整至4.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405100055058aed8f4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405100055058aed8f4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MCRB","LENZ"],"gpt_icon":0},{"id":"2432590892","title":"Seres Therapeutics Inc   预计每股亏损34美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432590892","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432590892?lang=zh_cn&edition=full","pubTime":"2024-05-03 21:46","pubTimestamp":1714743982,"startTime":"0","endTime":"0","summary":"   * Seres Therapeutics Inc    预计将于5月7日公布截至2024年3月31日的财报(，预计)。* 根据 LSEG 的数据，6 位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司预计将实现 25 万美元的营收。* LSEG 的分析师平均预计 Seres Therapeutics Inc 每股亏损 34 美分。* 华尔街对 Seres Therapeutics Inc 的 12 个月目标价中位数为 7.00 美元，高于其最新收盘价 1.11 美元。5月3日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCRB","LENZ"],"gpt_icon":0},{"id":"2417239460","title":"美国研究综述-Arrivent 生物制药公司、弗格森公司、目标公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2417239460","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417239460?lang=zh_cn&edition=full","pubTime":"2024-03-06 14:48","pubTimestamp":1709707680,"startTime":"0","endTime":"0","summary":"    路透社3月6日 - 华尔街证券分析师周三调整了对 Arrivent Biopharma、Ferguson 和 Target 等几家美国上市公司的评级和目标价。要闻             * Arrivent Biopharma Inc   ：杰富瑞给予买入评级             * 弗格森  ：杰富瑞将目标价从 222 美元上调至 244 美元             * Target Corp   ：汇丰银行将其评级从 \"持有 \"上调至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550577.SGD","BK4144","CTKB","ATIP","BK4023","AVAV","HCP","TGT","BK4588","FWRG","LU0348723411.USD","CRWD","STIM","TWLO","NKTR","PLAY","NTRA","FERG","MD","APGE","SG","LU0082616367.USD","FLGT","COLB","VYX","LU0053666078.USD","NWPX","AGS","LU0823414478.USD","NNN","EHAB","TRGP","JWN","LII","DYN","AXGN","AVBP","ROST","BOX","NTST","TSLA","CRGY","LU2272731600.USD","BASE","LFST","MCRB","BK4585","LU0823411888.USD","LU2272731782.SGD","IONS"],"gpt_icon":0},{"id":"2416464572","title":"Seres Therapeutics Inc   预计每股亏损50美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2416464572","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416464572?lang=zh_cn&edition=full","pubTime":"2024-03-01 22:11","pubTimestamp":1709302299,"startTime":"0","endTime":"0","summary":"   * Seres Therapeutics Inc    将于3月5日公布截至2023年12月31日的季度财报，预计该公司的季度收入将出现下降。* 根据LSEG的数据，6位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司的营收将从去年同期的101万美元下降65.2%，至35万美元。* LSEG 分析师对 Seres Therapeutics Inc 的平均预期是每股亏损 50 美分。* 华尔街对 Seres Therapeutics Inc 的 12 个月目标价中位数为 10.00 美元，高于其最新收盘价 1.14 美元。3月1日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCRB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.serestherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1449},{"period":"1month","weight":0.7244},{"period":"3month","weight":1.1879},{"period":"6month","weight":-0.0041},{"period":"1year","weight":-0.7308},{"period":"ytd","weight":-0.125}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Seres Therapeutics, Inc.于2010年10月根据特拉华州法律注册成立。该公司是一家商业阶段的微生物组疗法公司，专注于一类新型生物药物的开发和商业化，这些药物旨在通过调节微生物组来治疗疾病，通过将被破坏的微生物组的功能修复到非疾病状态来恢复健康。该公司还在设计微生物组疗法，这些疗法经过优化，可以去定植病原体并调节宿主功能，以减少和预防感染并诱导免疫耐受。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":-0.019469},{"month":2,"riseRate":0.111111,"avgChangeRate":-0.063465},{"month":3,"riseRate":0.666667,"avgChangeRate":0.013006},{"month":4,"riseRate":0.555556,"avgChangeRate":-0.019346},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.031547},{"month":6,"riseRate":0.444444,"avgChangeRate":0.000116},{"month":7,"riseRate":0.4,"avgChangeRate":-0.080767},{"month":8,"riseRate":0.666667,"avgChangeRate":0.741726},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.001429},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.092946},{"month":11,"riseRate":0.555556,"avgChangeRate":0.077509},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.086666}],"exchange":"NASDAQ","name":"Seres Therapeutics, Inc.","nameEN":"Seres Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Seres Therapeutics, Inc.(MCRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Seres Therapeutics, Inc.(MCRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Seres Therapeutics, Inc.,MCRB,Seres Therapeutics, Inc.股票,Seres Therapeutics, Inc.股票老虎,Seres Therapeutics, Inc.股票老虎国际,Seres Therapeutics, Inc.行情,Seres Therapeutics, Inc.股票行情,Seres Therapeutics, Inc.股价,Seres Therapeutics, Inc.股市,Seres Therapeutics, Inc.股票价格,Seres Therapeutics, Inc.股票交易,Seres Therapeutics, Inc.股票购买,Seres Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Seres Therapeutics, Inc.(MCRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Seres Therapeutics, Inc.(MCRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况